1. Home
  2. EDAP vs PRQR Comparison

EDAP vs PRQR Comparison

Compare EDAP & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$4.76

Market Cap

137.6M

Sector

Health Care

ML Signal

HOLD

Logo ProQR Therapeutics N.V.

PRQR

ProQR Therapeutics N.V.

HOLD

Current Price

$1.46

Market Cap

163.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDAP
PRQR
Founded
1979
2012
Country
US
US
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
137.6M
163.3M
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
EDAP
PRQR
Price
$4.76
$1.46
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$8.50
$7.67
AVG Volume (30 Days)
84.4K
407.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.15
$18.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.21
$1.08
52 Week High
$5.05
$3.10

Technical Indicators

Market Signals
Indicator
EDAP
PRQR
Relative Strength Index (RSI) 60.39 36.67
Support Level $4.23 $1.42
Resistance Level $4.81 $1.58
Average True Range (ATR) 0.43 0.10
MACD -0.02 0.01
Stochastic Oscillator 67.57 34.38

Price Performance

Historical Comparison
EDAP
PRQR

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Share on Social Networks: